UCC Book of Modules, 2012/2013: Pharmacy

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 18 x 1hr(s) Lectures; 10 x 3hr(s) Practicals; 6 x 2hr(s) Tutorials; Directed Study (27 hrs); 1 x 1day(s) Placements (1 day will be made to community pharmacies).

Module Co-ordinator: Dr Suzanne McCarthy, School of Pharmacy.

Lecturer(s): Professor Peter Weedle, School of Pharmacy; Professor Julia Kennedy, School of Pharmacy; Dr Stephen Byrne, School of Pharmacy; Dr Laura Jane Sahm, School of Pharmacy; Dr Suzanne McCarthy, School of Pharmacy; Dr Kieran Doran, School of Medicine.

Module Objective: To introduce the principles of professional aspects of Pharmacy.

Module Content: Introduction to UCC and to a Pharmacy Career. History of Pharmacy and structure of modern pharmacy. Prescriptions in context. Introduction to Professionalism and Ethical behaviour. Healthcare teams. Importance of communication skills in pharmacy. Health and illness: definitions and perceptions. Counselling skills. Applications of computing and information technology in practice. Sources of information. Dispensing process-theory and practice. Introduction into systems' failures. Pharmaceutical abbreviations and calculations. Risk minimisation in medication error.

Learning Outcomes: On successful completion of this module, students should be able to:
· Exhibit professional and ethical behaviour in the dispensing laboratories
· Identify and implement practices that minimise error
· Complete pharmaceutical calculations relevant to the dispensing practice
· Interpret pharmaceutical abbreviations
· Retrieve information efficiently using appropriate sources
· Articulate the contribution various professions make to the multidisciplinary team.

Assessment: Total Marks 100: End of Year Written Examination 70 marks; Continuous Assessment 30 marks (Continuous Assessment is composed of three elements: Laboratory classes (30 marks); Practical examination (assessed on a Pass/Fail basis) and completion of Placement and Log Book (assessed on a Pass/Fail basis)).

Compulsory Elements: End of Year Written Examination; Continuous Assessment (Laboratory classes; Practical examination; Completion of Placement and Log Book). Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% In addition students must achieve a Pass judgement in their Practical examination and Placement/Log Book and achieve at least 50% in each of the End of Year Written Examination and Continuous Assessment independently. Students who do not satisfy all of these requirements will fail the module overall.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School. The mark for laboratory classes will be carried forward).

Credit Weighting: 10

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 40 x 1hr(s) Lectures; 4 x 2hr(s) Tutorials; 15 x 2hr(s) Practicals; Directed Study (50hrs).

Module Co-ordinator: Dr Abina Crean, School of Pharmacy.

Lecturer(s): Professor Caitriona O'Driscoll, School of Pharmacy; Dr Abina Crean, School of Pharmacy; Dr Katie Ryan, School of Pharmacy.

Module Objective: To teach the principles and practices underlying the formulation and compounding of medicines.

Module Content: Pharmaceutical terminology. Pharmaceutical calculations. Basic statistics. An introduction to Preformulation and Physical Pharmacy. Physiochemical properties of Drug Substances. Rheology and Viscosity, Solubility and Dissolution, Partitioning, Interfacial Phenomena. Solubilisation. Colloids. Traditional dosage forms including: Oral Liquids, Solutions, Suspensions. Oral powders, Colouring, flavouring and sweetening agents. Semisolids: Gels, Pastes, Ointments, Creams, Emulsions and emulsifying agents, HLB values. Lotions, Dusting Powders. Rectal/Vaginal Drug Delivery; Suppositories, Enemas, Pessaries.

Learning Outcomes: On successful completion of this module, students should be able to:
· List and describe the various dosage form types and routes of administration
· Explain the basic physicochemical properties of pharmaceutical solutions and disperse systems
· Explain the importance of physicochemical properties to formulation design and dosage form performance
· Calculate correctly values of physicochemical properties, formulation quantities and dosage levels
· Design pharmaceutical oral and topical liquids, semisolids, powders, suppositories and pessaries formulations
· Relate the formulation of pharmaceutical oral and topical liquids, semisolids, suppositories and pessaries to their physicochemical properties and performance
· Design and prepare basic extemporaneous formulations in a simulated practice environment
· Calculate drug formulations, strength and quantities in a simulated practice environment.

Assessment: Total Marks 200: End of Year Written Examination 140 marks; Continuous Assessment 60 marks (Calculations midterm exam 20 marks, Theory midterm exam 20 marks, Laboratory Classes 20 marks, Formulation skills assessment (which will be assessed on a pass/fail basis)).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.Formulation skills Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% In addition students must achieve a Pass judgement in their Formulation Skills Assessment. Students who fail to satisfy this requirement will fail the module overall.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated ( as prescribed by the School of Pharmacy). Failed Formulation Skills Assessment must be repeated.

Credit Weighting: 15

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 66 x 1hr(s) Lectures; 18 x 1hr(s) Tutorials (Computer aided); 49 x 1hr(s) Practicals; Directed Study (including computer aided tutorials 72 hrs).

Module Co-ordinator: Dr Florence McCarthy, Department of Chemistry.

Lecturer(s): Dr Humphrey Moynihan, Department of Chemistry; Dr J J Keating, School of Pharmacy; Dr Florence McCarthy, Department of Chemistry; Dr Tim O'Sullivan, School of Pharmacy; Prof Anita Maguire, Faculty of Commerce.

Module Objective: Introduction to the chemical principles underpinning pharmacy, pharmaceutical and medicinal chemistry; and the significance of physics in the study of chemical and pharmaceutical substances.

Module Content: Fundamental structural and inorganic chemistry, including radiochemistry. Physiochemical principles: Gas laws, Hess's Law, Introduction to pharmaceutical thermodynamics and kinetics; Acids and bases. Electrochemistry. Light, atoms and molecules - spectroscopy. Introductory Organic Chemistry. Introduction to the structural chemistry of drugs; Acidity and basicity of pharmaceutical compounds; pKa. Pharmaceutical stereochemistry. Aromaticity in pharmaceutical compounds. Heterocyclic chemistry. Carbohydrates; amino acids, peptides and proteins, steroids, lipids and nucleic acids. Introductory Pharmaceutical Chemistry: an overview of pharmaceutical physicochemical properties.

Learning Outcomes: On successful completion of this module, students should be able to:
· Demonstrate the practical skills required to be a competent pharmaceutical chemist through a series of practical classes;
· Prepare and purify pharmaceutical compounds in a laboratory setting;
· Discuss topics in pharmaceutical chemistry and present their findings by means of seminars;
· Apply physical principles in order to describe the chemical properties of pharmaceutical compounds;
· Use the principles of organic chemistry to explain the origins, development and uses of medicines;
· Identify chemical structures and reactivity by means of functional group;
· Explain chemical reactions by means of reaction mechanisms;
· Identify and label stereoisomers of pharmaceutical molecules;
· Appreciate the importance of physiocochemical properties and different solid state forms of pharmaceutical materials.

Assessment: Total Marks 300: End of Year Written Examination 210 marks; Continuous Assessment 90 marks (including Practicals and MCQ).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must obtain at least 40% in each of the End of Year Written Examination and Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. The mark for Continuous Assessment is carried forward (where the mark is 40% or greater), No supplemental examination unless condition(s) are met (students must achieve at least 40% in Continuous Assessment at the Summer).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): PF1007

Co-requisite(s): None

Teaching Methods: 19 x 1hr(s) Lectures; 11hr(s) Tutorials (with case scenario presentations); 6 x 3hr(s) Practicals (Labs); 1 x 2day(s) Placements (Two days in a community pharmacy); Directed Study (27 hrs).

Module Co-ordinator: Dr Suzanne McCarthy, School of Pharmacy.

Lecturer(s): Professor Peter Weedle, School of Pharmacy; Dr Stephen Byrne, School of Pharmacy; Dr Suzanne McCarthy, School of Pharmacy; Dr Kieran Doran, School of Medicine.

Module Objective: To provide an understanding of the law, ethical, regulatory environment and practice governing the supply of medicines.

Module Content: The health-care system in Ireland; Pharmacists place in healthcare; evolving new roles for the pharmacist in the health-care team; the legal and ethical environment governing supply of medicines; international comparisons; the role of professional bodies; codes of practice; locations of pharmacy practice; structure of a prescription; labelling; record keeping; packaging and containers; regulation of medicines; controlled drugs. Poisons: classes and controls (to include those used in agriculture and horticulture); the duty of care; health services research. Minor illness and OTC questioning. Dispensing process, systems failure analysis, risk minimisation, practical dispensing, extemporaneous products.

Learning Outcomes: On successful completion of this module, students should be able to:
· Explain the legislation governing the sale and supply of medicinal products in Ireland
· Formulate and perform the extemporaneous dispensing of medicinal products
· Recognise and evaluate the ethical dilemmas which arise when dealing with the sale and supply of medicinal products in Ireland.

Assessment: Total Marks 100: End of Year Written Examination 70 marks; Continuous Assessment 30 marks (Continuous Assessment is composed of three elements: Laboratory classes (30 marks); Practical examination (assessed on a Pass/Fail basis) and completion of Placement and Log Book (assessed on a Pass/Fail basis)).

Compulsory Elements: End of Year Written Examination; Continuous Assessment (Laboratory classes; Practical examination; Completion of Placement and Log Book). Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% In addition, students must achieve a Pass judgement in their Practical examination and Placement/Log Book and achieve at least 50% in each of the End of Year Written Examination and Continuous Assessment independently. Students who do not satisfy all these requirements will fail the module overall.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School. The mark for laboratory classes will be carried forward).

Credit Weighting: 15

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): PF 1008

Co-requisite(s): None

Teaching Methods: 60 x 1hr(s) Lectures; 8 x 2hr(s) Tutorials; 15 x 3hr(s) Practicals; 32 x 1hr(s) Directed Study.

Module Co-ordinator: Dr Brendan Griffin, School of Pharmacy.

Lecturer(s): Professor Caitriona O'Driscoll, School of Pharmacy; Dr Abina Crean, School of Pharmacy; Dr Brendan Griffin, School of Pharmacy, Dr Katie Ryan, School of Pharmacy.

Module Objective: To study the principles of dosage form design and manufacture, including solid oral dosage forms (e.g. tablets, capsules) and sterile dosage forms (e.g. parenterals, opthalmics)

Module Content: Fundamental unit operations: fluid flow, heat transfer, mass transfer. Component properties: Powder properties (molecular, particulate, bulk), fluid properties; Primary unit operations: crystallation, evaporation, distillation, filtration, drying, particle size reduction and separation. Secondary pharmaceutical processes: granulation, blending, tabletting, coating, encapsulation. Development Pharmaceutics and scale up. Sterile pharmaceutical dosage forms: parenteral routes, Biopharmaceutics and formulation design of parenterals. Sterile manufacture: sterilisation, quality control of parenterals, aseptic processing, clean room design and control. Ophthalmic dosage forms. Pharmaceutical Packaging. Pharmaceutical statistics: descriptive statistics, Probability theory and distributions. Confidence intervals. Hypothesis testing. Statistical process control techniques. Quality Assurance in the manufacture and supply of pharmaceutical dosage forms: Good manufacturing practices, Quality control, role of regulatory bodies, drug development, clinical trials and registration, role of qualified person, validation.

Learning Outcomes: On successful completion of this module, students should be able to:
· Explain the impact of solid state and powder properties on formulation processing and performance
· Describe and discuss the key primary and secondary pharmaceutical manufacturing processes
· Apply the comprehension of formulation science to solid oral dosage forms (e.g. tablets, capsules) and sterile dosage forms (e.g. injections, eye drops)
· Demonstrate an understanding of the principles of sterile manufacture and control of contamination
· Apply comprehension of these principles to the aseptic compounding and processing of sterile dosage forms
· Be able to discuss the importance of Quality assurance and GMP in the development, manufacture and supply of medicines and the role of regulatory bodies in licensing medicines and manufacturers
· Describe the key statistical descriptors of pharmaceutical data and conduct statistical analysis using these descriptors
· Present aspects of pharmaceutical processing and regulation investigated as part of a team project in a workshop setting
· Design and aseptically prepare, in a simulated practice environment, formulations that are fit for intended use and do not place the patient at an unacceptable risk to health and safety.

Assessment: Total Marks 300: End of Year Written Examination 200 marks; Continuous Assessment 100 marks (Project 30 marks, Midterm test 40 marks, Laboratory Classes 30 marks, Aseptic Practical Examination (which will be assessed on a pass/fail basis)).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Aseptic Practical Examination. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% In addition students must achieve a Pass judgement in their Aseptic Practical Exam. Students who fail to satisfy this requirement will fail the module overall.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School of Pharmacy). Failed Aseptic Practical Examination must be repeated).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): PF1001/PF1101

Co-requisite(s): None

Teaching Methods: 28 x 1hr(s) Lectures; 11 x 1hr(s) Tutorials; 6 x 4hr(s) Practicals; Directed Study (18 hrs).

Module Co-ordinator: Dr J J Keating, School of Pharmacy.

Lecturer(s): Dr Daniel G. McCarthy, Department of Chemistry; Dr Humphrey Moynihan, Department of Chemistry; Dr J J Keating, School of Pharmacy; Dr Tim O'Sullivan, School of Pharmacy; Prof Anita Maguire, Faculty of Commerce.

Module Objective: To build on the content of PF1001/PF1101 by introducing fundamental aspects of medicinal and pharmaceutical chemistry

Module Content: History and development of organic and medicinal chemistry; structure-activity relationships; discussion of structure, physicochemical properties, mechanism of action and synthesis illustrated with examples from the range of anti-inflammatory and analgesic drugs; antifungal and antibiotic drugs.

Learning Outcomes: On successful completion of this module, students should be able to:
· Appreciate the origin and initial development of pharmaceutical chemistry.
· Explore the interactions of medicinal compounds with receptors and enzymes, in particular ligands for adrenergic and histamine receptors.
· Appreciate the design, structural diversity and synthesis of antibiotic, antifungal, analgesic and anti-inflammatory agents.
· Demonstrate and apply the practical skills learned at the laboratory sessions.

Assessment: Total Marks 100: End of Year Written Examination 70 marks; Continuous Assessment 30 marks (Practicals; Coursework).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must obtain at least 40% in each of the End of Year Written Examination and Continuous Assessment, independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. The mark for Continuous Assessment is carried forward (where the mark is 40% or greater), No supplemental examination unless condition(s) are met (students must achieve at least 40% in Continuous Assessment at the Summer).

Credit Weighting: 10

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): PF1001/PF1101

Co-requisite(s): None

Teaching Methods: 38 x 1hr(s) Lectures; 14 x 1hr(s) Tutorials; 8 x 4hr(s) Practicals; Directed Study (40 hrs).

Module Co-ordinator: Dr Humphrey Moynihan, Department of Chemistry.

Lecturer(s): Prof Jeremy Glennon, Department of Chemistry, Dr Simon Lawrence, Department of Chemistry; Dr Humphrey Moynihan, Department of Chemistry; Dr Dara Fitzpatrick, Department of Chemistry, Dr G. O'Riordan, Pfizer Ireland Pharmaceuticals; Dr Florence McCarthy, Department of Chemistry, Dr Daniel McCarthy, Department of Chemistry.

Module Objective: This module gives an introduction to methods of pharmaceutical analysis, which utilises chromatographic, spectroscopic and electroanalytical techniques. Principles of Quality Control. Principles of spectroscopic techniques used to determine the structure of medicinal compounds

Module Content: Physical principles of pharmaceutical analysis. Introduction to chromatography; HPLC, GC. Chemical equilibria: redox, acid-base, precipitation, extraction and complexation. Separation by precipitation, liquid-liquid and solid phase extraction. Spectroscopic methods: UV/visible, fluorescence, IR, near IR, Raman, atomic spectroscopy. Structural elucidation of medicinal compounds by high resolution Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry. Potentiometry (Ion selective electrodes), voltammetry, conductometry. Drug stability and accelerated stability testing

Learning Outcomes: On successful completion of this module, students should be able to:
· Participate in the operation of quality systems and regulatory measures
· Describe and apply analytical methods for characterising pharmaceutical solids
· Understand the working components and applications of Flame Atomic Absorption Spectroscopy
· Understand the essential development and rationale for the requirement of second and third generation instruments such as Graphite Furnace AA
· Determine the optimum conditions for the solvent extraction of organic and inorganic analytes from aqueous solution
· Identify and appreciate the roles of the instrumental components of gas and liquid chromatographs in the chromatographic process
· Understand the principles behind the spectroscopic techniques used to determine the structure of medicinal compounds and their applications
· Appreciate the molecular reasons and mechanisms of the drug degradation process.

Assessment: Total Marks 200: End of Year Written Examination 140 marks; Continuous Assessment 60 marks (Practicals; Coursework).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must obtain at least 40% in each of the End of Year Written Examination and Continuous Assessment, independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. The mark for Continuous Assessment is carried forward (where the mark is 40% or greater), No supplemental examination unless condition(s) are met (students must achieve at least 40% in Continuous Assessment at the Summer).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): PF1101, PF2101, PF2102

Co-requisite(s):

Teaching Methods: 28 x 1hr(s) Lectures; 12 x 1hr(s) Tutorials; 4 x 4hr(s) Practicals; Directed Study (20 hrs).

Module Co-ordinator: Dr J J Keating, School of Pharmacy.

Lecturer(s): Dr J J Keating, School of Pharmacy; Dr Barbara Doyle Prestwich, Department of Zoology, Ecology and Plant Science; Prof Anita Maguire, Faculty of Commerce.

Module Objective: To teach the principles of pharmacognosy; isolation and application of medicinal natural products.

Module Content: Methods in Pharmacognosy, morphology, microscopical technique, cytomorphology, analysis of acellular products, optical micrometrics, quantitative extractive values, extraction, separation and identification of constituents. Plants and their structure; orders and families; phytochemistry. Natural product chemistry: classification of biological molecules on the basis of chemical structure. Biosynthesis. Quality and reproducability of natural products.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss the origin of pharmacognosy and other related disciplines and their historic importance towards the development of modern medicine
· Understand plant morphology, both macroscopic and microscopic, the methods by which organisms store secondary products, and factors which affect the growth and reproducibility of plant derived natural products
· Understand the basics of plant primary metabolism and the biosynthetic origins of plant secondary products
· Discuss the importance of quality, efficacy and safety of naturally derived products
· Demonstrate and apply the practical skills learned at the laboratory sessions.

Assessment: Total Marks 100: End of Year Written Examination 70 marks; Continuous Assessment 30 marks.

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must obtain at least 40% in each of the End of Year Written Examination and Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. The mark for Continuous Assessment is carried forward (where the mark is 40% or greater), No supplemental examination unless condition(s) are met (students must achieve at least 40% in Continuous Assessment at the Summer).

Credit Weighting: 10

Teaching Period(s): Teaching Period 1.

No. of Students: Max 70.

Pre-requisite(s): PF1008 and PF2008

Co-requisite(s):

Teaching Methods: 40 x 1hr(s) Lectures; 10 x 1hr(s) Tutorials; 10 x 3hr(s) Practicals; Directed Study (50 hrs).

Module Co-ordinator: Professor Caitriona O'Driscoll, School of Pharmacy.

Lecturer(s): Professor Caitriona O'Driscoll, School of Pharmacy; Dr Brendan Griffin, School of Pharmacy.

Module Objective: To study the biopharmaceutical principles of drug delivery and the impact of formulation /dosage regimen design on the pharmacokinetics of drugs in the body.

Module Content: Biopharmaceutics: drug absorption, factors influencing bioavailability. Experimental models for assessing formulation effects on bioavailability (i.e. in vitro, in situ, in vivo models), Oral dosage form design, membrane transporters and drug disposition. Pharmacokinetics including absorption, distribution, metabolism and elimination mechanisms, calculation of pharmacokinetic parameters, compartmental and non-compartmental modeling, assessment of bioavailability, non-linear pharmacokinetics. Dosage regimen design: optimisation and individualisation. PK-PD relationships, Pharmacokinetic variability, Populations pharmacokinetics and Pharmacogenetics. Pharmacokinetics in drug discovery and development: Bioequivalence testing, IVIVC, Drug product selection and BCS.

Learning Outcomes: On successful completion of this module, students should be able to:
· Explain the impact of physicochemical properties, the dosage form/formulation and route of administration on the biological response of the drug.
· Provide experience in calculating the primary pharmacokinetic parameters of a drug following a single oral dose.
· Predict an optimal dosage regimen on the basis of the primary pharmacokinetic variables and the target therapeutic response.
· Predict patient specific dosage regimen adjustments on the basis of individual physiological parameters, e.g. % renal failure.
· Understand the importance of biopharmaceutical assessment of drugs in the context of lead selection, formulation development, bioavailability assessment and bioequivalence.

Assessment: Total Marks 200: End of Year Written Examination 140 marks; Continuous Assessment 60 marks (Midterm test 30 marks, Practicals 30 marks).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. The mark for Continuous Assessment is carried forward (Failed elements of Continuous Assessment must be repeated as prescribed by the School of Pharmacy).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): PF1001/PF1101, PF2001/PF2101, PF2002/PF2102

Co-requisite(s): PF3001

Teaching Methods: 22 x 1hr(s) Lectures; 3 x 4hr(s) Practicals; 10 x 1hr(s) Tutorials; Directed Study (20 hrs).

Module Co-ordinator: Dr Florence McCarthy, Department of Chemistry.

Lecturer(s): Dr J J Keating, School of Pharmacy; Dr Florence McCarthy, Department of Chemistry; Dr Orla Ni Dhubhghaill, Department of Chemistry; Prof Anita Maguire, Faculty of Commerce.

Module Objective: To develop a greater comprehension of pharmaceutical and medicinal chemistry, as applied to the design and synthesis of drugs.

Module Content: The chemistry of various classes of pharmaceutical agents. Topics will include all or some of the following: cardiovascular drugs, CNS drugs, anticancer drugs, metallodrugs, antiviral drugs.

Learning Outcomes: On successful completion of this module, students should be able to:
· Demonstrate the practical skill required to be a competent pharmaceutical chemist.
· Handle bio-active chemicals and materials with confidence and assurance.
· Use the principles of organic and inorganic chemistry to explain the development of medicines for the treatment of diseases such as cardiovascular disease, arthritis, viral diseases and cancer.
· Formulate and justify reaction mechanisms used in advanced organic synthesis.
· Discuss topics in medicinal chemistry using a structure based approach.

Assessment: Total Marks 100: End of Year Written Examination 70 marks; Continuous Assessment 30 marks.

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must obtain at least 40% in each of the End of Year Written Examination and Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. No supplemental examination unless condition(s) are met (there is no Autumn Supplemental for students failing Continuous Assessment at the Summer).

Credit Weighting: 10

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 48 x 1hr(s) Lectures; 24 x 1hr(s) Workshops; Directed Study (90 hrs); Placements (One week in a community pharmacy (40 hrs)).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Professor Peter Weedle, School of Pharmacy; Dr Stephen Byrne, School of Pharmacy; Dr Laura Jane Sahm, School of Pharmacy.

Module Objective: To have an appreciation of the appropriate, effective and safe use of medicines, paying particular attention to the: pharmacology, indications/ counselling requirements, legal and dispensing requirements and ethical issues relevant to the major classes of medicines. To acquire knowledge of safe and accurate dispensing of medicines within the group laboratory environment. To acquire the necessary skills to respond to the needs of patients in community pharmacy.

Module Content: Basic guidelines for responding to symptoms, the application of questioning, listening and explaining skills will be taught. Examples of appropriate and inappropriate ethical and professional behaviour. Assessment of OTC medicines. Distinction between minor illness and major disease. Counselling of patients on the appropriate use of drugs on a range of systems and areas, e.g. Cardiovascular System, Haematology, CNS, Inflammation, Analgesics, Respiratory, Oncology, Antimicrobrials, Endocrine, GIT, Renal and Hepatic systems. Toxicology. Factors affecting drug use and prescribing practice. Controlled drugs and unit dosage systems. Services to residential homes. Patient medication records. Statistics in pharmacy practice and in practice audit. Extended role of the pharmacist. Generic medicines. Parallel imports. Epidemiology. Alternative medications including herbal and homeopathy. Regulation of Pharmacy services and service development.

Learning Outcomes: On successful completion of this module, students should be able to:
· Observe and describe the manifestation of health and disease through the medium of the arts.
· Reflect on insights gained through the expereince of arts appreciation to enhance one's own clinical practice.
· Identify and implement practices that maximise patient safety.
· Complete pharmaceutical calculations relevant to the professional practice of pharmacy.
· Interpret pharmaceutical and medical abbreviations.
· Retrieve information efficiently using appropriate sources.
· Demonstrate an understanding of the importance of appropriate patient questioning and listening skills and apply these to factors influencing patients' perceptions of illness and health.
· Publicly communicate, through presentations and active participation in group discussions, on issues relevant to minor illnesses and major diseases.

Assessment: Total Marks 200: End of Year Written Examination 140 marks (End of Year Written Examination 100 marks, OSCE 40 marks); Continuous Assessment 60 marks (General MCQs; Workshops, Assignment; Presentations). Placement and Log Book Pass/Fail).

Compulsory Elements: End of Year Written Examination and OSCE; Continuous Assessment; Completion of Placement and Log Book. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% . In addition, students must achieve a Pass judgement in their Placement/Log Book and achieve at least 50% in each of the End of Year Written Examination and Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) and 1 x 1½ hr(s) OSCE.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) and 1 x 1½ hr(s) OSCE to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): PF1007 and PF2007

Co-requisite(s): None

Teaching Methods: 20 x 1hr(s) Lectures; 24 x 2hr(s) Workshops; Directed Study (42 hrs).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Professor Peter Weedle, School of Pharmacy; Professor Julia Kennedy, School of Pharmacy; Dr Stephen Byrne, School of Pharmacy; Dr Laura Jane Sahm, School of Pharmacy.

Module Objective: To have an appreciation of the appropriate, effective and safe use of medicines, paying particular attention to the pharmacology, indications/counselling requirements, legal and dispensing requirements and ethical issues relating to the major classes of medicines. To acquire knowledge of safe and accurate dispensing of medicines within the context of the group laboratory environment. To acquire the necessary skills to respond to the needs of patients in community pharmacy.

Module Content: Guidelines on querying a prescription, the application of questioning, listening and explaining skills. The choice of appropriate and effective medicines having due regard to the product authorisation.. The legal and ethical environment governing supply of medicines; international comparisons; the role of professional bodies; codes of practice; pharmacy practice in primary and secondary care; structure of a prescription; labelling; record keeping; packaging and containers; regulation of medicines; controlled drugs. Poisons: classes and controls (to include those used in agriculture and horticulture) and the duty of care. Toxicology. Design and execution of a research protocol, recognition of problems in design and identification of poor research practice. Minor illness and OTC questioning. Practical dispensing. Counselling of patients on the appropriate use of drugs on a range of systems and areas e.g. Cardiovascular System, Haematology, Central Nervous System, Inflammation, Analgesia, Respiratory, Oncology, Antimicrobials, Endocrine, Gastro intestinal, Renal and Hepatic. Factors affecting drug use and prescribing practice. Controlled drugs. Unit dosage systems. Services to residential homes. Patient medication records. Extended role of the pharmacist. Generic medicines. Parallel imports. Regulation of Pharmacy services and service development.

Learning Outcomes: On successful completion of this module, students should be able to:
· Display professional and ethical behaviour in the tutorials and lectures.
· Explain the patient counselling process.
· Identify and implement practices that maximise patient safety.
· Perform pharmaceutical calculations relevant to the professional practice of pharmacy.
· Dispense a patient's prescription safely.
· Interpret pharmaceutical and medical abbreviations. Retrieve information efficiently using appropriate sources.
· Describe the importance of appropriate patient questioning and listening skills and apply these to factors influencing patients' perceptions of illness and health.
· Formulate and perform the dispensing of medicinal products within a group laboratory environment.
· Publicly communicate, through presentations and active participation in group discussions, on issues relating to the legal, ethical and regulatory practices governing the supply of medicines.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Forensic MCQ 30 marks; Laboratory/Workshops 15 marks; Practical Examination 55 marks).

Compulsory Elements: Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% In addition, to pass Continuous Assessment students must achieve at least 70% in the Practical Examination and at least 50% in the Forensic MCQ. For students failing to achieve the requisite standard in the Practical Examination and/or the Forensic MCQ, the lower of the two marks will be returned for the module.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School). The mark for laboratory classes/workshops will be carried forward).

Credit Weighting: 5

Teaching Period(s): Teaching Period 1.

No. of Students: Max 70.

Pre-requisite(s): MB2444

Co-requisite(s): None

Teaching Methods: 20 x 1hr(s) Lectures; 4 x 3hr(s) Practicals; 2 x 1hr(s) Tutorials; Directed Study (20 hrs).

Module Co-ordinator: Dr Cormac Gahan, Department of Microbiology.

Lecturer(s): Professor Michael Prentice, Department of Pathology; Dr Cormac Gahan, Department of Microbiology, and Visiting Lecturers.

Module Objective: To provide detailed information on microbial pathogens, modes of infection and mechanisms of pathogenicity.

Module Content: Mechanisms of pathogenicity/toxicity; clinical presentations of infectious diseases; infections of the respiratory tract; infections of the gastrointestinal tract; cardiovascular infections; urinary tract infections; sexually transmitted diseases; congenital and childhood infections; travel-related and tropical diseases; fungal and parasitic infections; viral diseases; control of infection in the hospital and community; laboratory-based diagnosis of infection; combination anti-microbial chemotherapy; anti-viral therapy.

Learning Outcomes: On successful completion of this module, students should be able to:
· Outline the aetiology, pathology, symptoms and diagnosis of human infectious diseases
· Describe the molecular pathogenesis of specific infectious diseases with respect to symptoms
· Differentiate between diseases caused by bacteria, viruses, fungi and parasitic infectious agents
· Perform laboratory analyses towards the identification and differentiation of infectious agents
· Interpret data from diagnostic microbiological laboratory analyses.

Assessment: Total Marks 100: End of Year Written Examination 70 marks; Continuous Assessment 30 marks (MCQ 20 marks and Practical Reports 10 marks).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) (Students failing continuous assessment will be re-examined by MCQ) to be taken in Autumn.

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): PF1001/PF1101, PF2001/PF2101, PF2002/PF2102, PF3001, PF3002/PF3102

Co-requisite(s): None

Teaching Methods: 28 x 1hr(s) Lectures; 3 x 2hr(s) Workshops; 13 x 1hr(s) Tutorials; Directed Study (30 hrs).

Module Co-ordinator: Dr J J Keating, School of Pharmacy.

Lecturer(s): Dr J J Keating, School of Pharmacy; Dr Florence McCarthy, Department of Chemistry; Dr Orla Ni Dhubhghaill, Department of Chemistry; Prof Anita Maguire, Faculty of Commerce, and School of Pharmacy.

Module Objective: To teach advanced contemporary approaches in drug design and discovery.

Module Content: Combinatorial drug design, solid-phase synthesis, library generation and deconvolution, parallel synthesis; the development of peptidomimetic drugs from proteins; computer aided design of drugs; molecular modeling, QSAR; the medicinal chemistry of representative classes of drugs, for example, metallodrugs - inorganic drugs as therapeutic and diagnostic agents - and antiviral agents - strategy and medicinal chemistry.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and apply the theoretical skills required to be a competent pharmaceutical chemist in the area of drug design.
· Rationalize modern approaches to drug design including Structure-Activity Relationships (SAR) and high throughput strategies.
· Appreciate the issues associated with handling bio-active chemicals and materials with confidence and assurance.
· Use the principles of medicinal chemistry to explain the development of organic and inorganic medicines for the treatment of diseases such as arthritis, viral diseases and cancer.
· Discuss topics in medicinal chemistry using a structure based approach.

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks.

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must obtain at least 40% in both the End of Year Written Examination and Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. The mark for Continuous Assessment is carried forward (where the mark is 40% or greater), No supplemental examination unless condition(s) are met (students must achieve at least 40% in Continuous Assessment at the Summer).

Credit Weighting: 10

Teaching Period(s): Teaching Period 2.

No. of Students: Max 70.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 10 x 1hr(s) Lectures; 2 x 2hr(s) Tutorials; Other (Independent supervised research project, library research, report writing, project presentation, equivalent to approximately 180 hrs of directed study).

Module Co-ordinator: Professor Caitriona O'Driscoll, School of Pharmacy.

Lecturer(s): Professor Caitriona O'Driscoll, School of Pharmacy.

Module Objective: To develop the students' research skills

Module Content: Each final year student will be required to undertake a research project which will entail a literature survey, practical or fieldwork. The aims of the module are to teach the student how to: compile a relevant and up-to-date bibliography and review of the relevant literature; learn the appropriate experimental methods and techniques; collect and collate data; analyse the results including the use of statistical packages; logically interpret the data; discuss the findings in the context of the current state of the art; make justifiable conclusions. The students are required to present the project as an oral presentation and in written form.

Learning Outcomes: On successful completion of this module, students should be able to:
· Demonstrate the capacity to think independently and develop a specialist knowledge in a particular area
· Compile a relevant and up-to-date bibliography and literature review
· Plan, develop and carry out a programme of work to meet the defined objectives
· Learn and apply the appropriate experimental methods and techniques
· Logically interpret the data, discuss the findings and make justifiable conclusions
· Interact positively with their project supervisor by communicating knowledge, ideas and results in an effective manner
· Present results effectively in a written format.

Assessment: Total Marks 200: Continuous Assessment 200 marks (Research Performance, Written Project and Oral Presentation).

Compulsory Elements: Continuous Assessment. Literature Review. Written Project, Project Presentation. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: No Supplemental Examination.

Credit Weighting: 20

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 70.

Pre-requisite(s): None

Co-requisite(s):

Teaching Methods: 60 x 1hr(s) Lectures; 39 x 3hr(s) Workshops; Directed Study (246 hours); Placements (Placement in hospital pharmacy).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Dr Stephen Byrne, School of Pharmacy; Dr Suzanne McCarthy, School of Pharmacy, Guest lecturers.

Module Objective: To teach the principles of good clinical practice and the principles underlying the treatment of disease states, including ethical and professional behaviour and health education.

Module Content: Signs and symptoms of common disorders/diseases presenting to pharmacists in the community, the differentiation between minor illness or major disease, the choice of appropriate and effective therapy, the monitoring thereof and the counselling of the patient on the use of the recommended therapies and health promotion. The epidemiology, aetiology, pathophysiology, signs, symptoms, tests, diagnosis, drug treatment, pharmaceutical care plans, patient counselling, monitoring, and the use of "a green prescription" will be covered for: a) selected diseases of gastrointestinal, cardiovascular, respiratory, hepatic, renal, endocrine, obstetric and gynaecological, CNS (including psychiatric, neurological, muscloskeletal) and haematological systems and b) common conditions and infections encountered in dermatology, oncology, paediatric and elderly populations. Integrated case studies of patients with co-morbid disease, with focus on oncology, paediatric and elderly patients.

Learning Outcomes: On successful completion of this module, students should be able to:
· Describe the epidemiology, aetiology, pathophysiology, signs, symptoms, and tests leading to the diagnosis, of common disorders/diseases.
· Know the signs and symptoms of common disorders/diseases presenting to pharmacists in community and hospital practice.
· Differentiate between minor illness or major disease in community practice by appropriate questioning and refer or treat the patient accordingly.
· Choose the appropriate and effective therapy, for selected diseases of gastrointestinal, cardiovascular, respiratory, hepatic, renal, endocrine, obstetric and gynaecological, CNS (including psychiatric, neurological, muscloskeletal) and haematological systems and common conditions and infections.
· Be able to present cases and justify decisions for therapy in peer-group, tutorial and workshop settings.
· Monitor and counsel the patient on the use of recommended therapies and health promotion.
· Formulate pharmaceutical care plans and counsel patients.
· Use and recommend a "green" prescription appropriately.
· Apply their extensive knowledge of all subjects/modules taught in School of Pharmacy to date in order to optimise the use of medicines according to the following criteria:- effectiveness, appropriateness, safety, economics - for greater benefit of the patient.

Assessment: Total Marks 400: End of Year Written Examination 100 marks; Continuous Assessment 180 marks (MCQs, Case studies, project. Hospital Placement and Log Book Pass/Fail Judgement); Clinical Assessment 120 marks (1 x 2 hr OSCE).

Compulsory Elements: End of Year Written Examination; Continuous Assessment; Clinical Examination.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% In addition, students must achieve a Pass judgement in their Hospital Placement/Log Book and must obtain at least 50% in each of the End of Year Examinations and Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s) and 1 x 2 hr(s) OSCE.

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) and 1 x 2 hr(s) OSCE to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 10

Teaching Period(s): Teaching Period 1.

No. of Students: Max 70.

Pre-requisite(s): PF1008, PF2008 and PF3008

Co-requisite(s): None

Teaching Methods: 48 x 1hr(s) Lectures; 3 x 3hr(s) Tutorials; 6 x 3hr(s) Practicals; Directed Study (55 hrs).

Module Co-ordinator: Dr Katie Ryan, School of Pharmacy.

Lecturer(s): Professor Caitriona O'Driscoll, School of Pharmacy; Dr Abina Crean, School of Pharmacy; Dr Katie Ryan, School of Pharmacy.

Module Objective: To study and evaluate the design and formulation of targeted and other novel drug delivery systems and technologies.

Module Content: Major classes of rate-controlled drug delivery systems; rate-programmed, activation-modulated and feedback-regulated drug delivery systems. Technologies used to achieve rate-controlled drug delivery; matrix devices, multiparticulates, reservoir devices, functional coatings, osmotically controlled devices, drug eluting stents. Materials used in contolled drug delivery systems; polymers, bio-responsive, bioadhesive and biodegradable materials. Lipid based systems; SMEDDS and microemulsions. Nanotechnology, application and formulation approaches. Site-targeted drug delivery systems including: receptor mediated, carrier mediated, targeting to the intestinal lympathics, liver, cancer (tumours), cardiovascular, CNS and blood brain barrier. Design of novel drug delivery systems for various routes; parenteral (e.g. patient controlled pumps, depot injections, implants), buccal (e.g. sublingual tablets and sprays), nasal (e.g. sprays and aerosols), ocular (e.g. ocular inserts), oral (e.g. gastro-retentive, colon specific), vaginal (e.g. vaginal rings and sponges), rectal routes (e.g. rectal foams), transdermal (e.g. patches and iontophoretic devices) and pulmonary (e.g. dry powder inhalers, metered dose inhalers and nebulised preparations). Radiopharmaceuticals: Therapeutic and diagnostic applications of isotopes; preparation of radiopharmaceuticals; instrumentation. Opportunities for the Pharmacist in the Industrial setting.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss the challenges associated with formulation and drug delivery by different routes.
· Describe and critically assess traditional and novel formulations including devices that have been employed for drug delivery by different routes.
· Assess specific strategies, formulations and technologies that have been employed to achieve modified and targeted drug delivery.
· Evaluate formulation and drug delivery using specific techniques and interpret the outcomes.
· Justify the development of novel drug delivery systems based on relevant factors including drug properties, clinical considerations, route of delivery, vehicle characteristics and release profile etc.
· Design appropriate novel formulations in a practical setting in response to defined criteria.

Assessment: Total Marks 200: End of Year Written Examination 140 marks; Continuous Assessment 60 marks (Midterm exam 20 marks; Practicals 20 marks; Assignments 20 marks).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School of Pharmacy).

Credit Weighting: 10

Teaching Period(s): Teaching Period 2.

No. of Students: Max 70.

Pre-requisite(s): PF3008, PF4008

Co-requisite(s): None

Teaching Methods: 40 x 1hr(s) Lectures; 8 x 1hr(s) Tutorials; 5 x 3hr(s) Workshops; Directed Study (50 hrs).

Module Co-ordinator: Professor Caitriona O'Driscoll, School of Pharmacy.

Lecturer(s): Dr Daniel G. McCarthy, Department of Chemistry; Professor Caitriona O'Driscoll, School of Pharmacy; Dr Abina Crean, School of Pharmacy; Dr Brendan Griffin, School of Pharmacy; Dr Colman Casey, College of Medicine and Health; Dr John V (Eoin) Fleming, Department of Biochemistry; Dr Katie Ryan, School of Pharmacy; Dr Cormac Gahan, Department of Microbiology.

Module Objective: To study the basic science and clinical use of biotechnology-produced pharmaceuticals, with special emphasis on their production, stability, purity, formulation, and delivery

Module Content: Introduction to pharmaceutical biotechnology. Genetic basis of disease. The advantages and limitations of employing biotransformations (biocatalysis) - whole cells and enzymes in the production of chiral, enantioenriched APIs, pharmaceutical intermediates and fine chemicals. Stability and purity of biotech products; analytical techniques for biotech products; page and blotting techniques; immunoassays, chromatography, bioassays, mass-spec, molecular techniques. Nano-biotechnology and biosensors. Production and downstream processing of biotech products. Production and isolation of recombinant protein drugs including; insulin, hematopoietic growth factors, interlukins and interferons, growth hormones, monoclonal antibody-based pharmaceuticals, recombinant tissue-type plasminogen activator and Factor VIII. Targeting protein-protein interactions; genomics, proteomics and additional biotechnology-related techniques; polymerase chain reaction technology. Formulation and delivery of biotech products - peptide and protein drugs. Pharmacokinetics and pharmacodynamics of peptide and protein drugs. Gene therapy and gene delivery. Antisense oligonucleotides as drugs. Small interfering RNA. Vaccines, traditional and DNA vaccines. Regulatory affairs, biotech products. Economic considerations in medical biotechnology

Learning Outcomes: On successful completion of this module, students should be able to:
· Assess the role of biotransformations (biocatalysis) in the asymmetric synthesis of pharmaceuticals.
· Demonstrate an understanding of the genetic basis of disease and develop an appreciation for the different biotechnolological strategies which may be used in treatment.
· Evaluate the factors impacting on the production of recombinant proteins for clinical applications.
· Explain the processes involved in downstream processing, including, purification, sterile filling.
· Discuss regulatory affairs associated with biotech products.
· Describe traditional and novel vaccination strategies.
· Discuss the advantages and limitations of current gene targeting strategies, including viral, non-viral, oligonucleotide and siRNA approaches.
· Describe conventional process and formulation approaches for biopharmaceutical products
· Explain the impact of various factors that influence the stability of biopharmaceutical formulations.

Assessment: Total Marks 200: End of Year Written Examination 140 marks; Continuous Assessment 60 marks (In-term exam 40 marks; Pharmaceutics Industrial Report 20 marks).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School of Pharmacy).

Credit Weighting: 10

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 200hr(s) Other (Contact Time (55hrs) Preparation for Assessment (40 hrs) Independent Learning Time (105 hrs). Delivery methods include lectures, teleconference, seminars and workshops).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: Demonstrates and integrates knowledge of medications for safe medication management practices. Implements planned nursing/midwifery care/interventions to achieve the identified outcomes.
Evaluates patient progress towards expected outcomes and review plans in accordance with evaluation data and in consultation with the patient.

Module Content: The rationale for this module is to prepare the nurses/midwives to exercise a higher level of professional knowledge, practical skills and understanding of prescribing, within the context of this dynamic world of healthcare provision.
Principles of pharmacology. Systematic pharmacology, common dosage forms, pharmacodynamics and pharmacokinetics. Principles of prescribing and good prescribing practices. Pharmacoeconomics. The role of the Irish Medicines Board and legislation pertaining to the control and supply of medicines.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the principal pharmacological actions, including the mode of action and side effect profiles associated with a range of drugs.
· Discuss common dosage form systems and the differences that these may have on the management of a chronic or acute disease state.
· Explain the principles underlying pharmacokinetics and drug-drug interactions. Describe the legislative framework pertaining to the prescribing of medicines in Ireland.
· Formulate an appropriate treatment plan based on an understanding of the disease process present and a prediction of the likely success.

Assessment: Total Marks 200: Continuous Assessment 200 marks (Presentation of Cases 100 marks. OSCE/MCQ (Continuous) 100 marks. Log book of scenarios Pass/Fail award. Pass required in each element).

Compulsory Elements: Continuous Assessment. Attendance and participation at all timetabled teaching activities, submission of written work.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% In addition, students must achieve a Pass judgement in the Logbook and a Pass mark of 50% in the Presentation and OSCE/MCQ independently.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School of Pharmacy).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 or 2.

No. of Students: Max 20.

Pre-requisite(s): B.Pharm (or equivalent) and registered pharmacist with Mentor

Co-requisite(s): None

Teaching Methods: 1 x 2hr(s) Seminars (Teleconference/Webinars); Placements (15 hrs Clinical Placement); Directed Study (85 hrs).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Dr Stephen Byrne, School of Pharmacy, and Staff School of Pharmacy.

Module Objective: To develop a higher understanding of the importance of clinical research in the evaluation and ongoing monitoring of drug use. It will provide a comprehensive overview of biostatistics. The student will learn how to design and conduct clinical trials and how to interpret the results of clinical research, both as a researcher and as a reviewer.

Module Content: Biostatistics including the design of the different types of clinical studies and the statistical methods used to evaluate study findings, the different secondary research types and when each should be used, problems encountered with secondary research and how these can be minimised, how to read a research paper and the use of checklists to enable the reader to successfully interpret published clinical findings, the basis of evidence-based medicine and how it can be used to improve professional practice, evaluation of published papers using checklist, presentation of summary, main findings, possible relevance to clinical practice, identification of any problems in design, conduct, statistical evaluation and interpretation of results by authors and how these might influence validity of study/trial.

Learning Outcomes: On successful completion of this module, students should be able to:
· Demonstrate an understanding of the different kinds of possible research types in biomedical research.

· Demonstrate an understanding of the different trial designs and the statistical methods involved in evaluating study findings and apply these to specific examples.
· Demonstrate an understanding of the different secondary research types and apply these appropriately to given situations.

· Demonstrate an understanding of the evidence-based medicine and its application to improving professional practice.
· Read and critically appraise a research paper.

Assessment: Total Marks 100: Continuous Assessment 100 marks (4 statistics exercises, 1 written assignment. Oral if required).

Compulsory Elements: Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) (in lieu of continuous assessment) to be taken in Autumn.

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 or 2.

No. of Students: Max 20.

Pre-requisite(s): B.Pharm (or equivalent) and registered pharmacist with Mentor

Co-requisite(s): None

Teaching Methods: 1 x 2hr(s) Seminars (teleconferences/webinar); Placements (15 hrs clinical placement); Directed Study (85 hrs).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Dr Stephen Byrne, School of Pharmacy, and Lecturers, School of Pharmacy and National Centre for Pharmacoeconomics.

Module Objective: To understand: the importance of health economics in contemporary healthcare management; the principles of health economics, economic modelling, Quality Adjusted Life Years (QALY) sensitivity analysis; the economic principles used to measure the cost-effectiveness of medicines in clinical practice and in medical decision making.

Module Content: The basic economic techniques and how they can be adapted for use in the healthcare system. The allocation of funds and the rational use of medicines.

Learning Outcomes: On successful completion of this module, students should be able to:
· Apply the principles of health economics, economic modelling, QALY's sensitivity analysis for use in the health care system
· Apply the economic principles used to measure the cost-effectiveness of medicines in clinical practice and in medical decision making and allocation of funds in the rational use of medicines.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Case exercises and assignment 100 marks. Oral if required).

Compulsory Elements: Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) (in lieu of continuous assessment) to be taken in Autumn.

Credit Weighting: 15

Teaching Period(s): Teaching Periods 1 or 2.

No. of Students: Max 20.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 5 x 2hr(s) Tutorials (Teleconferences/Webinars); Directed Study (180 hours); Placements (Clinical Placements 45 hours).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To develop a higher knowledge of the major pharmacotherapeutic areas in order to promote a better understanding of the benefits and risks of use of these medicines in the clinical setting and to prepare the pharmacist for his/her evolving role within the hospital setting

Module Content: The major diseases of endocrine, musculoskeletal and central nervous systems, and the drugs that act directly on these systems will be examined. The potential changes in drug safety and efficacy that may occur in the presence of impaired function in any of these systems will be highlighted in order to ensure usage of the most appropriate drug at individual level, the rational use of anti-microbial agents. The expanded professional role of the clinical pharmacist will be highlighted, as will potential areas of future development.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the epidemiology, aetiology, pathophysiology, signs, symptoms, and tests leading to the diagnosis, of common disorders/diseases of endocrine, musculoskeletal and central nervous systems
· Choose the appropriate and effective therapy, for selected diseases of endocrine, musculoskeletal and central nervous systems,
· Monitor and the counsel the patient on the use of the recommended therapies and health promotion.
· Formulate pharmaceutical care plans and counsel patients
· Use and recommend a "green" prescription appropriately.

Assessment: Total Marks 300: End of Year Written Examination 120 marks (OSCE); Continuous Assessment 180 marks (Assignments, exercises, clinical case presentation 180 marks.).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must pass the End of Year Written Examination (OSCE) and achieve a minimum of 50% in Continuous Assessment independently. For students not meeting the End of Year Written Examination or Continuous Assessment requirement, the lower of the two marks calculated as a percentage of the total marks available, will be returned.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s) (OSCE).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) (OSCE) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School of Pharmacy).

Credit Weighting: 10

Teaching Period(s): Teaching Periods 1 or 2.

No. of Students: Max 20.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 4 x 2hr(s) Tutorials (teleconferences/webinars); Placements (clinical placements 30 hrs); Directed Study (120 hrs).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To develop a higher knowledge of the major pharmacotherapeutic areas in order to promote a better understanding of the benefits and risks of use of these medicines in the clinical setting and to prepare the pharmacists for his/her evolving role within the hospital/community setting.

Module Content: The major diseases and pharmacotherapy of special groups including children, the elderly, pregnant and breast-feeding women, patients with haematological or malignant conditions and patients undergoing critical care management including surgery (hospital candidates) or medication usage review (community candidates) in order to develop a higher understanding of the particular needs of these at risk categories. The expanded professional role of the clinical pharmacists will be highlighted, as will potential areas of future development.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the epidemiology, aetiology, pathophysiology, signs, symptoms, and tests leading to the diagnosis, of common disorders/diseases of special groups including children and the elderly in both primary and secondary care.
· Choose the appropriate and effective therapy, for selected diseases of special groups including children, the elderly, pregnant and breast-feeding women, patients with haematological or malignant conditions
· Monitor and counsel the patient on the use of the recommended therapies and health promotion
· Formulate pharmaceutical care plans and counsel patients
· Use and recommend a "green" prescription appropriately.

Assessment: Total Marks 200: End of Year Written Examination 60 marks (1 x 3 hr(s) OSCE); Continuous Assessment 100 marks (Assignments, exercises); Clinical Assessment 40 marks (End of Year Case presentation).

Compulsory Elements: End of Year Written Examination; Continuous Assessment; Clinical Examination.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must pass the End of Year OSCE Examination, achieve a minimum of 50% in Continuous Assessment, and End of Year Clinical Case presentation, independently. For students not meeting the End of Year Written Examination, End of Year Clinical Examination or Continuous Assessment requirement, the lowest of the four marks calculated as a percentage of the total marks available, will be returned.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s) (OSCE).

Requirements for Supplemental Examination: 1 x 3 hr(s) OSCE to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School of Pharmacy).

Credit Weighting: 30

Teaching Period(s): Teaching/Research Period 3.

No. of Students: Max 20.

Pre-requisite(s):

Co-requisite(s): None

Teaching Methods: 600 x 1hr(s) Other (Independent supervised research project , literature review, report writing, project presentation).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Dr Stephen Byrne, School of Pharmacy; Dr Laura Jane Sahm, School of Pharmacy; Dr Suzanne McCarthy, School of Pharmacy; Dr Teresa Barbosa, School of Pharmacy.

Module Objective: To carry out an independent research project of a particular aspect of Clinical Pharmacy.

Module Content: The approved research project will be supervised by a relevant member of UCC academic staff, jointly with an approved local supervisor. Each candidate is required to complete a dissertation based on research conducted. Oral presentation of the project may be required.

Learning Outcomes: On successful completion of this module, students should be able to:
· Develop an understanding of the planning, execution and reporting of a research project.
· Develop problem solving skills, project management skills and presentation skills.

Assessment: Total Marks 600: Continuous Assessment 600 marks (Interim Project proposal/Outline Ethical Application (50 marks). Research Dissertation (400 marks). Scientific Paper and Research Poster (150 marks)).

Compulsory Elements: Continuous Assessment. Oral if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: No Supplemental Examination.

Credit Weighting: 15

Teaching Period(s): Teaching Periods 1 or 2.

No. of Students: Max 20.

Pre-requisite(s):

Co-requisite(s): None

Teaching Methods: 5 x 2hr(s) Tutorials (teleconferences/webinars); Placements (45 hrs clinical placements); Directed Study (180 hrs).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To develop a higher knowledge of the major pharmacotherapeutic areas in order to promote a better understanding of the benefits and risks of the use of these medicines in the clinical pharmacy setting and to prepare the pharmacist for his/her evolving role within the hospital setting.

Module Content: The diseases of the major organ systems, gastrointestinal (including liver), respiratory, cardiovascular and renal systems and the drugs that act directly on these systems will be examined. The potential changes in drug safety and efficacy that may occur in the presence of impaired function in any of these systems will be highlighted in order to ensure usage of the most appropriate at individual level. The expanded professional role of the clinical pharmacist will be highlighted, as will potential areas of future involvement

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the epidemiology, aetiology, pathophysiology, signs, symptoms, and tests leading to the diagnosis, of common disorders/diseases of the gastrointestinal (including liver), respiratory, cardiovascular and renal systems
· Choose the appropriate and effective therapy, for selected diseases of the gastrointestinal (including liver), respiratory, cardiovascular and renal systems
· Formulate pharmaceutical care plans and counsel patients
· Use and recommend a "green" prescription appropriately.

Assessment: Total Marks 300: End of Year Written Examination 120 marks (OSCE); Continuous Assessment 180 marks (Assignments, exercises 180 marks).

Compulsory Elements: End of Year Written Examination; Continuous Assessment. Oral, if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must pass the End of Year Written Examination (OSCE) and achieve a minimum of 50% in Continuous Assessment independently. For students not meeting the End of Year Written Examination or Continuous Assessment requirement, the lower of the two marks calculated as a percentage of the total marks available, will be returned.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s) (OSCE).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) (OSCE) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School of Pharmacy).

Credit Weighting: 10

Teaching Period(s): Teaching Periods 1 or 2.

No. of Students: Max 20.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 2 x 2hr(s) Tutorials (Teleconferences/webinars); Placements (30 hrs Clinical Placement); Directed Study (120 hours).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To develop a higher understanding of pharmacology principles and their application in the clinical setting. To understand the benefit/risk evaluation of drugs in order to ensure the rational use of medicines; the mechanism of adverse drug reactions and drug interactions; medication errors and their prevention.

Module Content: Pharmacodynamics, mechanism of action of drugs, how drugs exert their effect in vivo and how this knowledge can be applied in the clinical setting. Pharmacokinetics, how drugs are handled in vivo and the clinical relevance of pharmacokinetics in practice; how the role of the clinical pharmacists is affected by regulatory requirements. The use of pharmacovigilance to monitor drug safety in practice, the pharmacist's role in the area of drug monitoring and managing drug-related side effects, the various mechanisms of drug-drug interactions, the ways medication errors can occur and the pharmacist's role in minimising their occurrence.

Learning Outcomes: On successful completion of this module, students should be able to:
· Apply complex pharmacology principles in the clinical setting
· Evaluate the benefit/risk evaluation of drugs in order to ensure the rational use of medicines
· Know the mechanisms of adverse drug reactions and drug interactions and how they can be prevented
· Know how medication errors occur, how they can be prevented and use pharmacovigilance to monitor drug safety in practice
· Discern the clinical relevance of pharmacokinetics in practice
· Know the regulatory requirements for supply and use of medicines in order to be able to practice effectively within their constraints.

Assessment: Total Marks 200: Continuous Assessment 200 marks (Assignments, exercises, clinical case presentation 200 marks).

Compulsory Elements: Continuous Assessment. Oral if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) (in lieu of Continuous Assessment) to be taken in Autumn.

Credit Weighting: 10

Teaching Period(s): Teaching Periods 1 and 2 and Teaching/Research Period 3.

No. of Students: Min 10, Max 30.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 200hr(s) Other (Contact Time (55hrs) Preparation for Assessment (40 hrs) Independent Learning Time (105 hrs). Delivery methods include lectures, teleconference, seminars and workshops).

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: Demonstrates and integrates knowledge of medications for safe medication management practices. Implements planned nursing/midwifery care/interventions to achieve the identified outcomes.
Evaluates patient progress towards expected outcomes and review plans in accordance with evaluation data and in consultation with the patient.

Module Content: The rationale for this module is to prepare the nurses/midwives to exercise a higher level of professional knowledge, practical skills and understanding of prescribing, within the context of this dynamic world of healthcare provision.
Principles of pharmacology. Systematic pharmacology, common dosage forms, pharmacodynamics and pharmacokinetics. Principles of prescribing and good prescribing practices. Pharmacoeconomics. The role of the Irish Medicines Board and legislation pertaining to the control and supply of medicines.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the principal pharmacological actions, including the mode of action and side effect profiles associated with a range of drugs.
· Discuss common dosage form systems and the differences that these may have on the management of a chronic or acute disease state.
· Critically analyse and explain the principles underlying pharmacokinetics and drug-drug interactions.
· Critically analyse the legislative framework pertaining to the prescribing of medicines in Ireland.
· Formulate an appropriate treatment plan based on an understanding of the disease process present and a prediction of the likely success.
· Provide a critical justification for treatment plan formulated.

Assessment: Total Marks 200: Continuous Assessment 200 marks (Presentation of Cases 100 marks. OSCE/MCQ (Continuous) 100 marks. Log book of scenarios Pass/Fail award. Pass required in each element).

Compulsory Elements: Continuous Assessment. Attendance and participation at all timetabled teaching activities, submission of written work.

Penalties (for late submission of Course/Project Work etc.): Where work is submitted up to and including 7 days late, 10% of the total marks available shall be deducted from the mark achieved. Where work is submitted up to and including 14 days late, 20% of the total marks available shall be deducted from the mark achieved. Work submitted 15 days late or more shall be assigned a mark of zero.

Pass Standard and any Special Requirements for Passing Module: 50% In addition, students must achieve a Pass judgement in the Logbook and a Pass mark of 50% in the Presentation and OSCE/MCQ independently.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School of Pharmacy).

Credit Weighting: 10

Teaching Period(s): Teaching Period 1. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 70hr(s) Directed Study (Distance learning); 2 x 1hr(s) Lectures; 3 x 2hr(s) Workshops; 1 x 3hr(s) Tutorials.

Module Co-ordinator: Dr Stuart Collins, Department of Chemistry.

Lecturer(s): Dr Stuart Collins, Department of Chemistry; Dr J J Keating, School of Pharmacy.

Module Objective: To introduce chemistry principles underpinning the design, development, manufacture, analysis and control of pharmaceutical compounds.

Module Content: Development of pharmaceutical chemistry; basic drug design and development; basic structure-activity relationships. Introduction to the structural chemistry of active pharmaceutical ingredients. Introductory Medicinal Chemistry; Acidity and basicity of pharmaceutical compounds; pKa. Pharmaceutical stereochemistry. Introductory Pharmaceutical Chemistry. Pharmaceutical analysis; Drug stability and accelerated stability testing. Principles of Pharmacognosy and Phytochemistry. Introduction to the chemistry of natural compounds; Chemical synthesis of naturally derived pharmaceutically active compounds.

Learning Outcomes: On successful completion of this module, students should be able to:
· Understand structure, stereochemistry and reactivity of organic compounds especially in relation to pharmaceuticals
· Comprehend the factors which affect acidity and basicity of pharmaceutical compounds
· Appreciate the information provided by a range of analytical techniques and their limitations
· Analyse pharmaceutical processes
· Understand and develop a systematic method for the analysis of drug compounds using a wide range of techniques
· Understand the role of analytical chemistry support to various pharmaceutical processes including the study of drug degradation, by-products and unknown impurities
· Demonstrate and apply the skills learned at the teleconference, workshop and other tutorial sessions.

Assessment: Total Marks 200: End of Year Written Examination 100 marks; Continuous Assessment 100 marks (written assignments and in term tests).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must obtain at least 40% in the End of Year Written Examination and Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s) (to be taken in the Spring).

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (There will be a special Supplemental Examination for students failing Continuous Assessment).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 35hr(s) Directed Study (Distance learning); 2 x 1hr(s) Lectures (Guest Speaker); 3 x 2hr(s) Workshops.

Module Co-ordinator: Dr Katie Ryan, School of Pharmacy.

Lecturer(s): Dr Abina Crean, School of Pharmacy.

Module Objective: To provide knowledge of the physicochemical principles of dosage form design. To teach the principles underlying the formulation and compounding of medicines

Module Content: Scientific principles of dosage form design: Physical pharmacy and physicochemical properties of drugs, Solubility, Drug dissolution, Rheology, Interfacial phenomena, Chemical and physical stability of drugs, Kinetics and drug product stability, Solid state properties, Crystalline and amorphous drug forms, Polymorphism, Micromeretics and particulate science. Review of dosage form design and manufacture: Solid oral dosage forms, Oral solutions, suspensions, emulsions, Semisolids: Gels, pastes, ointments, creams, Rectal/vaginal delivery systems, Topical/transdermal delivery systems, Rectal/Vaginal Drug Delivery systems, Modified release, dosage forms systems, Pulmonary/nasal drug delivery systems, Novel drug delivery systems

Learning Outcomes: On successful completion of this module, students should be able to:
· Define the basic phyisochemical properties affecting dosage form design.
· Explain the impact of physiochemical properties and formulation design on performance of dosage forms.
· Review the formulation design principles of the most common dosage forms.

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks (written assignments and in term tests).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 35hr(s) Directed Study (Distance learning); 2 x 1hr(s) Lectures (Guest Speaker); 3 x 2hr(s) Workshops.

Module Co-ordinator: Dr Abina Crean, School of Pharmacy.

Lecturer(s): Professor Caitriona O'Driscoll, School of Pharmacy; Dr Brendan Griffin, School of Pharmacy.

Module Objective: To study pharmaceutical industrial processes: bulk synthesis of API; secondary processing and bulk manufacture of dosage forms; packaging of finished products

Module Content: Fundamental unit operations: Heat transfer, Mass Transfer, Fluid Dynamics.
Primary Unit Operations: Crystallisation, Solid Liquid Extraction, Evaporation, Distillation, Filtration
Secondary pharmaceutical manufacturing and control: Bulk Powder Properties, Comminution, Blending/Mixing, Drying, Granulation, Tabletting, Coating, Encapsulation, Production of aerosols, Pharmaceutical Packaging

Learning Outcomes: On successful completion of this module, students should be able to:
· Define fundamental unit operations such as fluid flow, heat and mass transfer
· Explain the impact of physiochemical properties (e.g. powder properties) on formulation and performance of pharmaceutical dosage forms
· Define the key primary and secondary pharmaceutical manufacturing processes
· Apply the comprehension of formulation science to solid oral dosage forms (e.g. tablets, capsules)
· Define critical processing parameters for primary and secondary unit operations.

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks (written assignments and in term test).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 35hr(s) Directed Study (Distance learning); 2 x 1hr(s) Lectures (Guest Speaker); 3 x 2hr(s) Workshops.

Module Co-ordinator: Dr Brendan Griffin, School of Pharmacy.

Lecturer(s): Dr Brendan Griffin, School of Pharmacy; Dr Cormac Gahan, Department of Microbiology.

Module Objective: To provide an overview of the principles of Pharmaceutical Microbiology and to develop this understanding into an industrial manufacturing setting and the technology involved in the manufacture of sterile medicinal products

Module Content: Foundation Pharmaceutical Microbiology: Microbial structure, growth and metabolism, Prokaryotic and Eukaryotic Cell structures, Infectious diseases: prevention, vaccination and treatment, Medical Microbiology: Bacterial diversity and classification, Antibiotics, Manufacture of antibiotics, Fungi and anti-fungal agents; Protozoa and anti-infective therapies, Virology and anti-viral therapies, Immunology, Environmental microbiology.
Sterile processing and control: Water for pharmaceutical preparations, Sterilisation processes,
Aseptic manipulations/processing, Cleanroom design and control, Parenteral dosage form design and manufacture, Ophthalmic dosage form design and manufacture , QC testing for sterile products, Sterility testing, Particulate testing, Pyrogen/ endotoxin testing, Disinfection and Antiseptics, Preservation of pharmaceutical products, Barrier isolation technology , Medical devices.

Learning Outcomes: On successful completion of this module, students should be able to:
· Explain the basic principles of pharmaceutical microbiology
· Understand the principles of manufacture and control of sterile pharmaceutical dosage forms.

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks (written assignments and in term tests).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 35hr(s) Directed Study (Distance learning); 1 x 2hr(s) Lectures; 1 x 2hr(s) Workshops; Workshops.

Module Co-ordinator: Professor Caitriona O'Driscoll, School of Pharmacy.

Lecturer(s): Dr Abina Crean, School of Pharmacy; Dr Brendan Griffin, School of Pharmacy.

Module Objective: To understand the effects of formulation on in vivo performance of medicinal products. To explain how new drugs are developed from the initial screening in-vitro to the types of pivotal clinical studies normally undertaken in order to achieve licensing.

Module Content: Introduction to Biopharmaceutics and Pharmacokinetics: Principles of drug absorption, dististribution, metabolism and excretion. Impact of dosage form and route of administration on drug pharmacokinetics, Influence of formulation and physiochemical properties on bioavailability, Assessment of biopharmaceutical properties, Assessment of pharmacokinetic properties, In vitro in vivo correlations
Drug Development and licensing of IMPs: Pharmaceutical Profiling in drug discovery and Lead selection; Drug product development, pre-formulation studies and scale-up; Clinical Trial design and IMP legislation; Principles of Good Clinical Practice (GCP); Marketing Authorisation Applications; Scale up and Post Approval changes; Bioequivalence and generic applications; Biowaivers and Biopharmaceutical Drug Classification Scheme

Learning Outcomes: On successful completion of this module, students should be able to:
· Explain the impact of physicochemical properties, the dosage form/formulation and route of administration on the biological response of the drug
· Provide experience in calculating the primary pharmacokinetic parameters of a drug
· Understand the importance of biopharmaceutical assessment of drugs in the context of lead selection, formulation development, bioavailability assessment and bioequivalence
· Understand the regulatory framework for the development of investigational medicinal products.

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks (written assignments and in-term tests).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 35hr(s) Directed Study (Distance learning); 2 x 1hr(s) Lectures (Guest Speaker); 1 x 2hr(s) Workshops.

Module Co-ordinator: Professor Caitriona O'Driscoll, School of Pharmacy.

Lecturer(s): Dr Brendan Griffin, School of Pharmacy; Dr Colman Casey, College of Medicine and Health; Dr John V (Eoin) Fleming, Department of Biochemistry.

Module Objective: To study the basic science and the applications of biotechnology derived pharmaceuticals, with special emphasis on their production, formulation delivery and clinical use.

Module Content: Introduction of pharmaceutical biotechnology: Fundamental molecular biology, Genetic basis of disease, Protein structure, stability and analysis, Biochemistry of protein processing, Blotting techniques and immunoassays, Polymerase chain reaction technology, Genomics, proteomics and additional biotechnology-related techniques, Industrial Biochemistry, Pharmacogenetics and Pharmacogenomics, Gene therapy and gene delivery. Vaccines, traditional and DNA vaccines.
Processing and control of Biopharmaceuticals: Sources of Biopharmaceuticals, Stability and purity of biotech products; Analytical techniques and QC testing for biotech products; Production and downstream processing of biotech products. Formulation and delivery of biotech products - peptide and protein drugs. Registration of biotech product and Biosimilars.

Learning Outcomes: On successful completion of this module, students should be able to:
· Explain the basics of molecular biology and its application to pharmaceutical biotechnology
· Review the techniques for processing and purification of biopharmaceuticals.

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks (written assignments and in-term tests).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 35hr(s) Directed Study (Distance learning); 2 x 1hr(s) Lectures (Guest Speaker); 3 x 2hr(s) Workshops.

Module Co-ordinator: Dr Katie Ryan, School of Pharmacy.

Lecturer(s): Dr Brendan Griffin, School of Pharmacy.

Module Objective: The use of statistics in the control and monitoring of pharmaceutical processes will be explained, along with the use of statistical experimental design in process development and improvement.

Module Content: Pharmaceutical statistics: Introduction to variation, Precision, accuracy and bias, Repeatability and Reproducibility, Introduction to probability theory, Normal probability distributions, parametric versus non parametric testing; Z test; T test; Two sample t tests; F testing and Chi tests; ANOVA; Determination of sample size; Correlation and Regression analysis;
Statistical process control: Process monitoring and Sampling statistics; Historical development of SPC methodology; Control charts; Process capability; Six Sigma approach; Acceptance sampling strategies; Military rules; Application of statistic principles to Design of Experiments; Application of statistic principles to validation studies; Process Analytical Technology (PAT)

Learning Outcomes:

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks (written assignments and in term tests).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 35hr(s) Directed Study (Distance learning); 2 x 1hr(s) Lectures (Guest Speaker); 3 x 2hr(s) Workshops.

Module Co-ordinator: Dr Abina Crean, School of Pharmacy.

Lecturer(s): Dr Abina Crean, School of Pharmacy; Dr Brendan Griffin, School of Pharmacy.

Module Objective: To understand the principles of pharmaceutical plant design and the validation implications for new plant and/or processes.

Module Content: Pharmaceutical Plant design: Manufacturing site considerations, Design and utilization of utilities, Process layout and design considerations, HVAC, Microbial/Particulate monitoring procedures, Environmental considerations, Health and Safety considerations, Product Containment, Materials of fabrication and construction, Equipment requirements and finishes
Pharmaceutical Validation: Scope and types of validation strategies, DQ, IQ, OQ, PQ concepts
Commissioning, Process validation, Cleaning validation, Analytical validation, Process automation and validation of process control systems (GAMP), Training

Learning Outcomes: On successful completion of this module, students should be able to:
· Explain the principles of pharmaceutical plant design
· Explain the concepts of pharmaceutical qualification and validation
· Describe approaches to vailidation throughout the pharmaceutical life cycle
· Prepare and discuss a qualification and/or validation document
· Discuss the advantages and disadvantages of various validation approaches in a workshop setting.

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks (written assignments and in term tests).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (There will be a special Supplemental Examination for students failing Continuous Assessment).

Credit Weighting: 5

Teaching Period(s): Teaching Period 1. (Run on a biennial basis).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 35hr(s) Directed Study (Distance learning); 2 x 1hr(s) Lectures (Guest Speaker); 3 x 2hr(s) Workshops.

Module Co-ordinator: Dr Brendan Griffin, School of Pharmacy.

Lecturer(s): Dr Brendan Griffin, School of Pharmacy.

Module Objective: Introduction to the Quality systems as it applies to the manufacture of medicinal products.

Module Content: Basics of Quality and a Quality system. Evolution of quality in manufacturing and GMP. Legislation of medicinal products for human and veterinary use.
Principles of GMP: Personnel, Premises and Equipment, Documentation, Production, Quality Control, Contract manufacture and analysis, Complaints and Recall procedures, Auditing - internal and external. Calibration and PM, Deviation procedures, Change control - purpose and practise, Corrective action and Preventive action system,
Role of Regulatory bodies, IMB, EMEA, FDA, Licensing and enforcement, Assessment and registration, Package labelling, Pharmacovigilance,
GMP guidelines for API and IMP manufacturers, Medical devices legislation, Comparing GMP between EU, US etc, Mutual recognition agreements, Other regulatory bodies: HSA, EPA etc., Patent life management
ISO series, ICH and CTD's, CGMP for 21st century, Risk management, ICH Q8, Q9, Q10, Total quality management

Learning Outcomes: On successful completion of this module, students should be able to:
· Understand the importance of QA/GMP/QC in the development, manufacture and supply of medicines and the role of regulatory bodies in licensing medicines and manufacturers.
· Review the latest trends in quality management, process control and regulatory perspectives.

Assessment: Total Marks 100: End of Year Written Examination 80 marks; Continuous Assessment 20 marks (written assignments and in-term tests).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated (as prescribed by the School).

Credit Weighting: 30

Teaching Period(s): Teaching Period 2 and Teaching/Research Period 3. (Year 2 (6 months)).

No. of Students: Max 25.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 3 x 2hr(s) Workshops (Research techniques); Directed Study (Independent supervised research project, literature review, report writing, project presentation, equivalent to at least 360 hrs of directed study).

Module Co-ordinator: Dr Brendan Griffin, School of Pharmacy.

Lecturer(s): Dr Abina Crean, School of Pharmacy; Professor Caitriona O'Driscoll, School of Pharmacy; Prof Anita Maguire, Faculty of Commerce, Staff, School of Pharmacy.

Module Objective: To carry out an independent research project of a particular aspect of Pharmaceutical technology and quality systems

Module Content: Prior to undertaking the research project students will receive instruction in research methodology, project planning and execution. The approved research project will be supervised by a relevant member of UCC academic staff, jointly with an approved industrial supervisor or interdepartmentally at UCC. Each candidate is required to complete a dissertation based on research conducted. Oral presentation of the project is required.

Learning Outcomes: On successful completion of this module, students should be able to:
· Demonstrate the capacity to think independently and develop a specialist knowledge in a particular area.
· Compile a relevant and up-to-date bibliography and literature review
· Plan, develop and carry out a programme of work to meet the defined objectives
· Apply the appropriate experimental methods and techniques
· Logically interpret the data, discuss the findings and make justifiable conclusions
· Demonstrate problem solving skills, project management skills and presentation skills
· Interact positively with their project supervisor by communicating knowledge, ideas and results in an effective manner
· Present results effectively in a written format.

Assessment: Total Marks 600: Continuous Assessment 600 marks (Research Performance 200 marks and Dissertation (Minor Thesis) 400 marks).

Compulsory Elements: Continuous Assessment. Research Dissertation (Minor Thesis), Oral if required.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must obtain at least 40% in each element of Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: Revise and resubmit the dissertation (as prescribed by the School). The mark for Research performance is carried forward. No supplemental examination unless conditions are met (students must achieve at least 40% in Research Performance).

Credit Weighting: 10

Teaching Period(s): Teaching Period 2.

No. of Students: Max 10.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 30hr(s) Directed Study; 40 x 1hr(s) Lectures; 4 x 2hr(s) Tutorials.

Module Co-ordinator: Professor Caitriona O'Driscoll, School of Pharmacy.

Lecturer(s): Professor Caitriona O'Driscoll, School of Pharmacy; Dr Abina Crean, School of Pharmacy; Dr Brendan Griffin, School of Pharmacy; Dr Katie Ryan, School of Pharmacy; Dr Cormac Gahan, Department of Microbiology; Dr Colman Casey, College of Medicine and Health.

Module Objective: To provide an extensive overview of the process for development of a pharmaceutical by a biotechnology company. Emphasis will be placed on formulation and processing approaches, product development process, regulatory (FDA and EMA) requirements and intellectual property considerations.

Module Content: Incorporation of biotechnology product into finished production dosage form. Excipient choices, processing techniques; freeze drying, spray drying, aseptic processing, novel drug delivery techniques. Characteristics and properties of biopharmaceutical drugs and delivery systems. The stages of the drug development process and the information required for filing a biotechnology product with the governmental regulatory authorities (FDA and EMA). The regulations that govern the development, manufacture and sales of biotechnology products. The module will include an introduction to quality assurance, cGMP, validation and quality control testing requirements.

Learning Outcomes: On successful completion of this module, students should be able to:
· Describe the role of regulatory bodies in licensing medicines and manufacturers.
· Relate the importance of Quality assurance and GMP in the development, manufacture and supply of medicines and the role of regulatory bodies in licensing medicines and manufacturers.
· Define the key primary and secondary manufacturing processes for biopharmaceuticals
· Explain the key formulation approaches for biopharmaceuticals
· Critically assess the impact of processing, formulation and handling on the stability of biopharmaceutical drugs and products.
· Summarise the design, development and regulatory approval of biopharmaceutical products.

Assessment: Total Marks 200: End of Year Written Examination 150 marks; Continuous Assessment 50 marks (Project).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 40%.

End of Year Written Examination Profile: 1 x 3 hr(s) paper(s) to be taken in Spring.

Requirements for Supplemental Examination: 1 x 3 hr(s) paper(s) to be taken in Autumn. The mark for Continuous Assessment is carried forward.

Credit Weighting: 5

Teaching Period(s): Teaching Period 1.

No. of Students: Min 5, Max 30.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 10 x 1hr(s) Lectures (Direct contact); 15 x 1hr(s) Tutorials (Online).

Module Co-ordinator: Dr Katie Ryan, School of Pharmacy.

Lecturer(s): Dr Katie Ryan, School of Pharmacy; Staff, School of Pharmacy.

Module Objective: To study the principles underlying formulation and dosage form design

Module Content: Pharmaceutical terminology. Pharmaceutical calculations. An introduction to Preformulation and Physical Pharmacy. Physiochemical properties of drug substances. Rheology and viscosity, Solubility and dissolution, Interfacial phenomena. Solubilisation. Colloids. Micromeritics, particle size. Solid state properties of drugs and excipients, melting point, polymorphism, crystal form. Formulation and properties of traditional pharmaceutical dosage forms and associated routes of delivery including: Oral Liquids: solutions, suspensions, excipients, emulsions and emulsifying agents, HLB values, lotions. Water for pharmaceutical preparations. Oral powders, Solid dosage forms: tablets, capsules. Semisolids: gels, pastes, ointments, creams. Dusting Powders. Rectal/vaginal drug delivery; suppositories, enemas, pessaries, foams. Formulation of inhaled delivery systems. Parenteral products, Testing of pharmaceutical dosage forms

Learning Outcomes: On successful completion of this module, students should be able to:
· Explain physicochemical properties of drug substances and pharmaceutical systems
· Evaluate the impact of physicochemical properties on dosage form design and performance
· List the characteristics associated with dosage forms and drug delivery systems
· Describe how characteristics associated with specific delivery routes influence dosage form design and performance
· Describe the formulation of pharmaceutical dosage forms
· Characterise dosage forms
· Apply the comprehension of drug delivery principles to the design and formulation of dosage forms
· Calculate values of physicochemical properties and formulation quantities.

Assessment: Total Marks 100: End of Year Written Examination 60 marks; Continuous Assessment 40 marks (Design Project 25 marks; Questions requiring research on module topic 15 marks).

Compulsory Elements: End of Year Written Examination; Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 40% Students must obtain at least 40% in each of the End of Year Written Examination and Continuous Assessment independently. For students who do not satisfy this requirement, the lower of the two marks, calculated as a percentage of the total mark for the module, will be returned.

End of Year Written Examination Profile: 1 x 1½ hr(s) paper(s).

Requirements for Supplemental Examination: 1 x 1½ hr(s) paper(s) to be taken in Autumn. No supplemental examination unless condition(s) are met (There is no supplemental examination for students failing continuous assessment in the Summer).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 20.

Pre-requisite(s): Undergraduate degree in pharmacy or related health sciences profession.

Co-requisite(s): None

Teaching Methods: 4 x 2hr(s) Tutorials; 30hr(s) Other (Clinical experience); 62hr(s) Directed Study.

Module Co-ordinator: Professor Julia Kennedy, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To develop a greater understanding of the major pharmacotherapeutic issues in order to promote a better comprehension of the benefits and risks of use of these medicines in the clinical setting in the treatment of asthma.

Module Content: The pharmacology, pathophysiology, pharmacotherapy and drug delivery systems of asthma in order to develop a greater understanding of the particular needs of patients with asthma.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the epidemiology, aetiology, pathophysiology, signs, symptoms and tests leading to the diagnosis of asthma.
· Recommend, as part of a health care team, appropriate and effective therapy, for asthma.
· Monitor and counsel the patient on the use of the recommended therapies and health promotion for asthma.
· Formulate pharmaceutical care plans and counsel patients with asthma.
· Use and recommend a "green" prescription appropriately.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Assignments, exercises 60 marks; Logbook case studies 40 marks).

Compulsory Elements: Continuous Assessment. Completion of logbook.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must achieve a minimum of 50% in continuous assessment and 50% in the logbook requirement independently. For students not meeting continuous assessment requirement or the logbook requirement, the lower of the two marks calculated as a percentage of the total marks available, will be returned. There is no supplemental examination for students failing the logbook.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 1½ hr(s) OSCE to be taken in Autumn. The mark for Continuous Assessment is carried forward (A pass in the logbook), No supplemental examination unless condition(s) are met (A pass in the logbook).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 20.

Pre-requisite(s): Undergraduate degree in pharmacy or related health sciences profession

Co-requisite(s): None

Teaching Methods: 4 x 2hr(s) Tutorials; 30hr(s) Other (Clinical experience); 62hr(s) Directed Study.

Module Co-ordinator: Professor Julia Kennedy, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To develop a greater understanding of the major pharmacotherapeutic issues of diabetes in order to promote a better comprehension of the benefits and risks of use of these medicines in the clinical setting in the treatment of Type I and Type II diabetes.

Module Content: The pharmacology, pathophysiology, pharmacotherapy and drug delivery systems of Type I and Type II diabetes in order to develop a greater understanding of the particular needs of patients with these diseases.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the epidemiology, aetiology, pathophysiology, signs, symptoms and tests leading to the diagnosis of Type I and Type II diabetes.
· Recommend, as part of a healthcare team, the appropriate and effective therapy, for Type I and Type II diabetes.
· Monitor and counsel the patient on the use of the recommended therapies and health promotion for Type I and Type II diabetes.
· Formulate pharmaceutical care plans and counsel patients with Type I and Type II diabetes.
· Use and recommend a "green" prescription appropriately.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Assignments, exercises 60 marks; Logbook case studies 40 marks).

Compulsory Elements: Continuous Assessment; Completion of logbook.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must achieve a minimum of 50% in continuous assessment, and 50% in the logbook requirement independently. For students not meeting continuous assessment requirement or the logbook requirement, the lower of the two marks calculated as a percentage of the total marks available, will be returned. There is no supplemental examination for students failing the logbook.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 1½ hr(s) OSCE to be taken in Autumn. The mark for Continuous Assessment is carried forward (A pass in the logbook), No supplemental examination unless condition(s) are met (A pass in the logbook).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 20.

Pre-requisite(s): Undergraduate degree in pharmacy or related health sciences profession

Co-requisite(s): None

Teaching Methods: 5 x 2hr(s) Lectures; 1 x 8hr(s) Workshops; 50hr(s) Directed Study.

Module Co-ordinator: Dr J J Keating, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To introduce the principles of herbal medicine; clinical indications, formulations, quality and safety of herbal medicinal products.

Module Content: History of herbal medicine. Whole herb extracts and other herbal formulations. Taxonomy. Sources and range of organisms used in herbal medicine. Active constituents found in herbal medicines. Quality control of herbal medicines. Legislation overseeing herbal products. Information sources. Use of herbal products in the treatment of minor ailments. Clinical indications and toxicology of herbal products. Interactions of herbal medicines with conventional medicines.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss the origin of herbal medicine and their connections with orthodox medicine.
· Discuss the range of formulations available of herbal medicinal products and understand methods for their manufacture.
· Appreciate and critically evaluate all aspects of quality control and legislation pertaining to herbal products.
· Discuss the clinical indications suitable for herbal medicine usage and their use in conjunction with orthodox medicines.
· Source and critically evaluate reliable information concerning herbal medicines.
· Demonstrate and apply the practical skills learned at the workshop session.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Assignment 85 marks; Workshop 15 marks).

Compulsory Elements: Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated.

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 20.

Pre-requisite(s): Undergraduate degree in Pharmacy, Medicine or Nursing

Co-requisite(s): None

Teaching Methods: 2 x 8hr(s) Lectures; 1 x 4hr(s) Other (Clinical visit/workshop); 50hr(s) Directed Study.

Module Co-ordinator: Dr Stephen Byrne, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To introduce the principles of coagulation; clinical indications, formulations, quality and safety issues related to coagulation therapy. To enable autonomous practice in dealing with fundamental and more complex problems of oral anticoagulation management.

Module Content: The course will provide its students with the management skills required to operate and oversee the running of an oral anticoagulant clinic. Key features of the learning will include; the coagulation cascade; the means by which warfarin inhibits this cascade; typical drug and food interactions encountered with warfarin; how to predict typical warfarin dosages and how to understand the rationale behind a patient's International Normalised Ratio (INR); mechanisms of action, indication and drug-drug/drug disease interactions associated with coagulation; the place of low molecular weight heparins in anticoagulation; new therapeutic options available.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss the theory underpinning anticoagulation management.
· Explain the pharmacology of vitamin K antagonists, their side effects, antidotes, interactions and dosing schedules.
· Describe in detail how patients should be initiated and managed on warfarin therapy for a range of indications.
· Discuss the common co-morbidities and co-medications which may affect the patient's INR.
· List the steps to be taken when a patient presents with an INR which is out of range. These steps should demonstrate knowledge of the management of anticoagulation and prevention of complications on the basis of current guidelines and existing research evidence.
· Discuss the roles of the multidisciplinary team in the safe management of anticoagulation.
· Compile an audit plan for an anticoagulation clinic (including but not limited to: external and internal quality control, performance criteria of the clinic, assessment of the way the service is provided etc.
· Discuss the place of new therapies in the management of coagulopathies.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Assignment/exercises case scenarios 60 marks; MCQ 20 marks; Logbook case studies 20 marks).

Compulsory Elements: Continuous Assessment. Completion of logbook, clinical visit/workshop, Attendance at lectures.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: Marks in passed element(s) of Continuous Assessment are carried forward, Failed element(s) of Continuous Assessment must be repeated.

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 20.

Pre-requisite(s): Undergraduate degree in Pharmacy or related health sciences profession

Co-requisite(s): None

Teaching Methods: 4 x 2hr(s) Tutorials; 30hr(s) Other (Clinical experience); 62hr(s) Directed Study.

Module Co-ordinator: Professor Julia Kennedy, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To develop a greater understanding of the major pharmacotherapeutic issues of dyslipidaemia and hypertension in order to promote a better comprehension of the benefits and risks of use of these medicines in the clinical setting in the treatment of dyslipidaemia and hypertension.

Module Content: The pharmacology, pathophysiology, pharmacotherapy and drug delivery systems of dyslipidaemia and hypertension in order to develop a greater understanding of the particular needs of patients with these diseases.

Learning Outcomes: On successful completion of this module, students should be able to:
· Critically discuss and explain the epidemiology, aetiology, pathophysiology, signs, symptoms and tests leading to the diagnosis of dyslipidaemia and hypertension
· Recommend, as part of a healthcare team, the appropriate and effective therapy, for dyslipidaemia and hypertension
· Monitor and counsel the patient on the use of the recommended therapies and health promotion for dyslipidaemia and hypertension
· Formulate pharmaceutical care plans and counsel patients with dyslipidaemia and hypertension
· Use and recommend a "green" prescription appropriately.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Assignments, exercises 60 marks; Logbook case studies 40 marks).

Compulsory Elements: Continuous Assessment. Completion of logbook.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must achieve a minimum of 50% in continuous assessment and 50% in the logbook requirement independently. For students not meeting continuous assessment requirement or the logbook requirement, the lower of the two marks calculated as a percentage of the total marks available, will be returned. There is no supplemental examination for students failing the logbook.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 1½ hr(s) OSCE to be taken in Autumn. The mark for Continuous Assessment is carried forward (a pass in the logbook), No supplemental examination unless condition(s) are met (a pass in the logbook).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 20.

Pre-requisite(s): Undergraduate degree in pharmacy or related health sciences profession

Co-requisite(s): None

Teaching Methods: 4 x 2hr(s) Tutorials; 30hr(s) Other (Clinical experience); 62hr(s) Directed Study.

Module Co-ordinator: Professor Julia Kennedy, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy.

Module Objective: To develop a greater understanding of the major pharmacotherapeutic issues in order to promote a better comprehension of the benefits and risks of use of medicines in the clinical setting in the treatment of Congestive Heart Failure, Atrial Fibrillation and Stroke.

Module Content: The pharmacology, pathophysiology, pharmacotherapy and drug delivery systems of congestive heart failure and stroke in order to develop a greater understanding of the particular needs of patients with these diseases.

Learning Outcomes: On successful completion of this module, students should be able to:
· Critically discuss and explain the epidemiology, aetiology, pathophysiology, signs, symptoms and tests leading to the diagnosis of congestive heart failure and stroke.
· Recommend, as part of the healthcare team, the appropriate and effective therapy, for congestive heart failure and stroke.
· Recommend, as part of a healthcare team, the appropriate and effective therapy, for congestive heart failure and stroke.
· Monitor and counsel the patient on the use of the recommended therapies and health promotion for congestive heart failure and stroke.
· Formulate pharmaceutical care plans and counsel patients with congestive heart failure and stroke.
· Use and recommend a "green" prescription appropriately.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Assignments, exercises 60 marks; logbook case studies 40 marks).

Compulsory Elements: Continuous Assessment. Completion of logbook.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must achieve a minimum of 50% in continuous assessment and 50% in the logbook requirement independently. For students not meeting continuous assessment requirement or the logbook requirement, the lower of the two marks calculated as a percentage of the total marks available, will be returned. There is no supplemental examination for students failing the logbook.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 1½ hr(s) OSCE to be taken in Autumn. The mark for Continuous Assessment is carried forward (A pass in the logbook), No supplemental examination unless condition(s) are met (A pass in the logbook).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 and 2.

No. of Students: Max 20.

Pre-requisite(s): Undergraduate degree in pharmacy or related health sciences profession

Co-requisite(s): None

Teaching Methods: 4 x 2hr(s) Tutorials (Teleconferences); 30hr(s) Other (Clinical Experience); 62hr(s) Directed Study.

Module Co-ordinator: Professor Julia Kennedy, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy, Mr Tony Cullinane, UCC/CUH and Ms Sinead Byrne, CUH.

Module Objective: To develop a higher knowledge of issues in patients presenting to community pharmacists requesting advice regarding disorders, diseases or infections of the eyes; in order to promote a better understanding of these eye conditions; to ensure pharmacists understand the difference between major illnesses and minor diseases and refer patients appropriately.

Module Content: The pharmacology, pathophysiology, pharmacotherapy and drug delivery systems of eye diseases, infections and disorders in order to develop a higher understanding of the particular needs of patients with these diseases, infections and disorders.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the different eye diseases and eye infections which community pharmacists may encounter including their epidemiology, aetiology, pathophysiology, signs, symptoms and tests leading to the diagnosis.
· Choose the appropriate and effective therapy, for minor conditions.
· Monitor and counsel the patient on the use of the recommended therapies and health promotion for eye diseases and disorders.
· Recommend the appropriate products for the different types of contact lenses in use.

Assessment: Total Marks 100: Continuous Assessment 100 marks (60 marks Assignments, Exercises and MCQ; 40 marks Log Book Case Studies).

Compulsory Elements: Continuous Assessment, Completion of Log Book.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must achieve a minimum of 50% in continuous assessment and 50% pass in the log book requirement independently. For students not meeting the continuous assessment requirement or the logbook requirement, the lower of the two marks calculated as a percentage of the total marks available, will be returned. There is no Autumn supplemental examination for students failing the log book or achieving less than 50% in continuous assessment.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 1½ hr(s) OSCE (A pass continuous assessment mark is carried forward) to be taken in Autumn. No supplemental examination unless condition(s) are met (a pass in the log book).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 or 2 or Teaching/Research Period 3.

No. of Students: Max 20.

Pre-requisite(s): Undergraduate degree in pharmacy or related health sciences profession

Co-requisite(s): None

Teaching Methods: 4 x 2hr(s) Tutorials; 30hr(s) Other (Clinical experience); 62hr(s) Directed Study.

Module Co-ordinator: Professor Julia Kennedy, School of Pharmacy.

Lecturer(s): Staff, School of Pharmacy, Dr Michael Byrne, Student Health.

Module Objective: To develop a greater understanding of the common conditions encountered when travelling abroad and their appropriate prophylaxis and treatment.

Module Content: The presentation, pathophysiology, pharmacotherapy and prophylaxis of common conditions encountered when travelling abroad.

Learning Outcomes: On successful completion of this module, students should be able to:
· Discuss and explain the most common conditions (including diarrhoea, vomiting, malaria, HIV, hepatitis, insect bites, sunburn, sunstroke) encountered when travelling abroad including their epidemiology, aetiology and pathophysiology, signs, symptoms and prevention.
· Recommend as part of a health care team, appropriate and effective therapy, for these common travel conditions.
· Monitor and counsel the patient on the use of the recommended therapies, vaccination schedules and health promotion for these common travel conditions.
· Formulate pharmaceutical care plans and counsel patients with these conditions.
· Use and recommend a "green" prescription appropriately.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Assignments, exercises 60 marks; Logbook case studies 40 marks).

Compulsory Elements: Continuous Assessment.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50% Students must achieve a minimum of 50% in continuous assessment and 50% in the logbook requirement independently. For students not meeting continuous assessment requirement or the logbook requirement, the lower of the two marks calculated as a percentage of the total marks available will be returned. There is no supplemental examination for students failing the logbook.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: 1 x 1½ hr(s) OSCE to be taken in Autumn. The mark for Continuous Assessment is carried forward (a pass in the logbook). No supplemental examination unless condition(s) are met (a pass in the logbook).

Credit Weighting: 5

Teaching Period(s): Teaching Periods 1 or 2.

No. of Students: Max 50.

Pre-requisite(s): None

Co-requisite(s): None

Teaching Methods: 3 x 8hr(s) Lectures (/Workshops/Laboratory sessions); 76 x 1hr(s) Directed Study.

Module Co-ordinator: Dr Simon Lawrence, Department of Chemistry.

Lecturer(s): Staff, Department of Chemistry; Staff, School of Pharmacy.

Module Objective: To develop an appreciation of the pharmaceutical solid state and its characterisation.

Module Content: The crystalline state and crystallography, X-ray diffraction methods. Reveiw of crystallisation theory; phase and morphology; crystal size and shape; influence on bioavailability. Solvent selection. Purity and enantiopurity. Impact of solvent and impurities on phase and morphology. Analytical techniques investigating power characteristics, solubility and dissolution.

Learning Outcomes: On successful completion of this module, students should be able to:
· Demonstrate an understanding of the principles and practice of diffraction techniques, crystallography and the crystalline state.
· Select appropriate solvent systems for crystallization of active pharmaceutical ingredients, rationalise the effects of solvents and impurities on crystal phase and morphology.
· Explain the impact of crystalline and particulate properties on drug dissolution and bioavailability.
· Discuss the theory and applications of a range of techniques to determine powder particle size, surface area, porosity, surface energy and hygroscopicity.
· Explain the theory and application of a range of thermal analysis techniques in the analysis of drug powders.

Assessment: Total Marks 100: Continuous Assessment 100 marks (Pass/Fail based on attendance and participation in problem solving and discussion seminars monitored by academic staff).

Compulsory Elements: Minimum 75% attendance monitored by class register.

Penalties (for late submission of Course/Project Work etc.): Work which is submitted late shall be assigned a mark of zero (or a Fail Judgement in the case of Pass/Fail modules).

Pass Standard and any Special Requirements for Passing Module: 50%.

End of Year Written Examination Profile: No End of Year Written Examination.

Requirements for Supplemental Examination: Opportunity to repeat module in subsequent year; no supplemental examination.


		Book of Modules 2012/2013
		Pharmacy

Book of Modules 2012/2013

Pharmacy